Physician profile
Jay Anthony Hendrix
NPI 1851304380
$5,279.15
in general payments reported to CMS, 2019-2025
19 companies · $817 in 2025
The $817 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $877 · 2020: $320 · 2021: $582 · 2022: $839 · 2023: $816 · 2024: $1,029 · 2025: $817.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,653 · Education: $8.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,652.99 |
| Education | $8.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $1,225.71 | 2019-2025 | Tremfya, Simponi Aria, Simponi |
| Abbvie INC. | $1,199.78 | 2019-2025 | |
| Ucb, INC. | $494.94 | 2019-2025 | Bimzelx, Cimzia |
| Pfizer INC. | $376.37 | 2019-2025 | |
| Novartis Pharmaceuticals Corporation | $348.14 | 2019-2025 | |
| Lilly USA, LLC | $313.47 | 2019-2025 | Olumiant, Taltz, Ebglyss |
| Regeneron Healthcare Solutions, INC. | $263.21 | 2020-2025 | Dupixent, Libtayo |
| Genzyme Corporation | $247.02 | 2019-2025 | |
| Amgen INC. | $166.83 | 2019-2025 | Otezla, Otezla |
| E.R. Squibb & Sons, L.L.C. | $154.54 | 2022-2025 | Sotyktu |
| Dermavant Sciences, INC. | $148.60 | 2023-2024 | Vtama |
| Leo Pharma INC. | $87.83 | 2021-2023 | Adbry |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $77.64 | 2019-2021 | |
| Incyte Corporation | $45.76 | 2024-2025 | Opzelura |
| Organon LLC | $38.80 | 2025 | Hadlima, Vtama |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $31.98 | 2023 | |
| Celgene Corporation | $24.20 | 2019 | |
| Sandoz INC. | $22.73 | 2023 | Hyrimoz |
| Galderma Laboratories, L.P. | $11.60 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jay Hendrix listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.